# US 10,500,184 B2 · 3-methanesulfonylpropionitrile for treating inflammation and/or pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,500,184 B2
- Document ID: US10500184B2
- Status: Granted
- Kind: B2
- Application number: 16/139,351
- Filed: 2018-09-24
- Published: 2019-05-09
- Granted: 2019-12-10
- Earliest claimed: 2010-12-15
- Assignees: Olatec Therapeutics LLC
- Applicants: Olatec Therapeutics LLC
- Inventors: Joseph St. Laurent
- Web page: https://patentgrep.com/patent/US10500184B2

## CPC

- A61K 31/275: Nitriles; Isonitriles
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07C 317/28: with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of 3-methanesulfonylpropionitrile or a pharmaceutically acceptable solvate thereof, wherein the composition is in an oral form of tablets, capsules, or syrups.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound is at least 90% (w/w) pure.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the compound is at least 95% (w/w) pure.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the oral form is a tablet.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the oral form is a capsule.

### Claim 6

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of 3-methanesulfonylpropionitrile or a pharmaceutically acceptable solvate thereof, wherein the composition is in a topical form of gels, creams, lotions, or patches.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound is at least 90% (w/w) pure.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the compound is at least 95% (w/w) pure.

### Claim 9 (depends on 6)

The pharmaceutical composition according to claim 6, the compound is in an amount of about 0.5-10% (w/w).

### Claim 10 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the pharmaceutically acceptable carrier is an emollient selected from the group consisting of: lauryl lactate, diethylene glycol monoethylether, caprylic/capric triglyceride, octisalate, silicone fluid, Squalene, and sunflower oil.

### Claim 11 (depends on 6)

The pharmaceutical composition according to claim 6, wherein the pharmaceutically acceptable carrier is a permeation enhancer selected from the group consisting of lactate esters and diethylene glycol monoethylether.

### Claim 12 (depends on 11)

The pharmaceutical composition according to claim 11, wherein the permeation enhancer is diethylene glycol monoethylether.

### Claim 13 (depends on 11)

The pharmaceutical composition according to claim 11, further comprising acrylates/C10-30 alkyl and tris(2-hydroxyethyl)amine.